P73, P63 and mutant P53: Members of protein complexs floating in cancer cells

25 Years of p53 Research

Volumn , Issue , 2005, Pages 223-232

  Monti, Olimpia ^a   Damalas, Alexander ^a   Strano, Sabrina ^a   Blandino, Giovanni ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33646802302     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4020-2922-6_10     Document Type: Chapter

References (55)

1. Agami R., Blandino G., Oren M., and Shaul. Y. Interaction of c-Abl and p73 and their collaboration to induce apoptosis. Nature 1999;399:809-13.
2. Almog N., and Rotter V. Involvement of p53 in cell differentiation and development. Biochem. Biophys. Acta. 1997;1333:F1-27.
3. Aas T., Borresen A. L., Geisler S., Smith-Sorensen B., Johnsen H., Varhaug J. E., Akslen L. A., and Lonning P. E. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med. 1996;2:811-4.
4. Basu S., Totty N. F., Irwin M. S., Sudol M., Downward J. Akt phosphorylates the Yesassociated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol. Cell. 2003;11:11-23.
5. Blandino G., Levine A. J., and Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene, 1999, 18:477-85.
6. Bensaad, K., Le Bras M., Unsal K., Strano S., Blandino G., Tominaga O., Rouillard D., and Soussi T. Change of conformation of the DNA binding domain of p53 is the only key element for binding of and interference with p73. J. Biol. Chem. 2003;278:10546-10555.
7. Bergamaschi D., Gasco M., Hiller L., Sullivan A., Syed N., Trigiante G., Yulug I., Merlano M., Numico G., Comino A., Attard M., Reelfs O., Gusterson B., Bell A. K., Heath V., Tavassoli M., Farrel P. J., Smith P., Lu X., and Crook T. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 2003;3:387-402.
8. Bullock A. N., and Fersht A. R. Rescuing the function of mutant p53. Nat. Rev. Cancer 2001;1:68-76.
9. Cho, Y. J., S. Gorina, P. D. Jeffrey, and N. P. Pavletich. Crystal structure of a p53 tumor suppressor DNA complex: understanding tumorigenic mutations. Science 1994;265:346-355.
10. Costanzo A., Merlo P., Pediconi N., Fulco M., Sartorelli V., Cole P. A., Fontemaggi G., Fanciulli M., Schiltz, L., Blandino, G., Balsano C., and Levrero M. DNA damagedependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol. Cell 2002;9:175-86.
11. De Laurenzi V., Costanzo A., Barcaroli D., Terrinoni A., Falco, M., Annichiarico-Petruzzelli M., Levrero M., and Melino G. Two new p73 splice variants, gamma and delta, with different transcriptional activity. J. Exp. Med. 1998;188:1763-68.
12. De Laurenzi V., Raschellà G., Barcaroli D., Annichiarico-Petruzzelli, M., Ranalli, M., Catani M. V., Tanno B., Costanzo A., Levrero M., and Melino G. Induction of neuronal differentiation by p73 in a neuroblastoma cell line. J. Biol. Chem. 2000;275:15226-231.
13. Di Como C. J., Gaiddon C., and Prives C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol. Cell. Biol. 1999;19:1438-49.
14. Dittmer D., Pati S., Zambetti G., Chu S., Teresky A. K., Moore M., Finlay C.,. and Levine A. J. Gain of function mutations in p53. Nat. Genet. 1993;4:42-6.
15. Flores E. R., Tsai K. Y., Crowley D., Sengupta S., Yang A., McKeon F., and Jacks T. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002;416:560-564.
16. Fontemaggi G., Gurtner A., Strano S., Higashi Y., Sacchi A., Piaggio G., and Blandino G. The transcriptional repressor ZEB regulates p73 expression at the cross-road between proliferation and differentiation. Mol. Cell. Biol. 2001;24:8461-470.
17. Fontemaggi G., Kela I., Amariglio N., Rechavi G., Krishnamurthy J., Strano S., Sacchi A., Givol D., and Blandino G. Identification of direct p73 target genes combining DNA microarray and chromatin immunoprecipitation analyses. J. Biol Chem. 2002;277:43359-368.
18. Frazier M. W., He X., Wang J., Gu Z., Cleveland J. L., and Zambetti G. P. Activation of cmyc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain. Mol. Cell. Biol. 1998;18:3735-43.
19. Gaiddon C., Lokshin, M., Ahn, J., Zhang T., and Prives. C. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol. Cell. Biol. 2001;21:1874-87.
20. Gong J. G., Costanzo A., Yang, H. Q., Melino G., Kaelin W. G., Levrero M., and Wang, J. Y. J. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999;39:806-9.
21. Gualberto A., Aldape K., Kozakiewicz K., and Tlsty, T. D. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc. Natl. Acad. Sci. U S A 1998;95:5166-71.
22. Hainaut P., Soussi T., Shomer B., Hollstein M., Greenblatt M., Hovig E., Harris C. C., and Montesano R. Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res. 1997;25:151-7.
23. Haley O., Michalovitz D., and Oren M. Different tumor-derived p53 mutants exhibit distinct biological activities. Science 1990;250:113-6.
24. Hollstein M., Soussi T., Thomas G., von Brevern M. C., and Bartsch H. p53 gene alterations in human tumors: perspectives for cancer control. Recent Results Cancer Res. 1997;143:369-89.
25. Hussain, S. P., and Harris C. C.. Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res. 1998;58:4023-37.
26. Jost C. A., Marin M. C., and Kaelin W. G.. p73 is a human p53 related protein that can induce apoptosis. Nature 1997;389:191-4.
27. Irwin M., Kondo K., Marin M. C., Cheng L. S., Hahn W. C., and Kaelin W. G. Jr. Chemosensitivity linked to p73 function. Cancer Cell 2003;3:403-10.
28. Kaelin W. G., Jr. The emerging p53 gene family. J. Natl. Cancer Inst. 1999;91:594-8.
29. Kaghad M., Bonnet H., Yang A., Creancier L., Biscan J. C., Valent A., Minty A., Chalon P., Lelias J. M., Dumont, X., Ferrara, P., McKeon F., and Caput D. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997;90:809-19.
30. Levine A. J. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
31. Levrero M., De Laurenzi V., Costanzo A., Gong J., Wang J. Y., and Melino G. The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J. Cell. Sci. 2000;113:1661-70.
32. Li R., Sutphin P. D., Schwartz D., Matas D., Almog, N., Wolkowicz R., Goldfinger N., Pei H., Prokocimer M., and Rotter. V. Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene 1998;16:3269-77.
33. Lin, J., A. K. Teresky, and A. J. Levine. Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants. Oncogene 1995;10:2387-90.
34. Marin M. C., Jost C. A., Brooks L. A., Irwin M. S., O'Nions J., Tidy J. A., James, N., McGregor J. M., Harwood C. A.,. Yulug I. G., Vousden, K. H., Allday M. J., Gusterson B., Ikawa S,. Hinds P. W., Crook T., and Kaelin W. G. Jr. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat. Genet. 2000;25:47-54.
35. Matas D., Sigal A., Stambolsky P., Milyavsky M., Veisz L., Schwartz D., Goldfinger N., and Rotter V. Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis. EMBO J. 2001;20:4163-72.
36. Michalovitz D., Halevy O., Oren M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive. Cell 1990;62:671-80.
37. Mills A. A., Zheng B., Wang, X. J., Vogel H., Roop D. R., and Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999;398:708-13.
38. Morena A. R., Riccioni S., Marchetti A., Tartaglia Polcini A., Mercurio A. M., Blandino G., Sacchi A., and Falcioni R. Expression of β4 integrin subunit induces monocytic differentiation of 32D/v-Abl cells. Blood 2002;100:96-106.
39. Osada M., Ohba M., Kawahara C., Ishioka C., Kanamaru R., Katoh I., Ikawa Y., Nimura Y., Nakagawara A., Obinata, M., and Ikawa S. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat. Med. 1998;4:839-43.
40. Prives C., and Hall P. A. The p53 pathway. J Pathol. 1999;187:112-26.
41. Sigal A., and Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res. 2000;60:6788-93.
42. Soddu S., Blandino G., Scardigli R., Coen S., Marchetti A., Rizzo M. G., Bossi G., Cimino L., Crescenzi M., and Sacchi A. Interference with p53 protein inhibits hematopoietic and muscle differentiation. The Journal of Cell Biology 1996;134:193-204.
43. Strano S., Munarriz E., Rossi, M., Cristofanelli B., Shaul Y., Castagnoli, L., Levine, A. J., Sacchi, A., Cesareni, G., Oren M. and Blandino. G. Physical and functional interaction between p53 mutants and different isoforms of p73. J. Biol. Chem. 2000;275:29503-12.
44. Strano S., Fontemaggi G., Costanzo A., Rizzo M. G., Monti O., Baccarini A., Del Sal G., Levrero M., Sacchi A., Oren M. and Blandino G. Physical interaction with human tumor derived p53 mutants inhibits p63 activities. J. Biol Chem. 2002;277:18817-826.
45. Strano S., Munarriz E., Rossi M., Cristofanelli B., Castagnoli L., Shaul Y., Sacchi A., Oren M., Sudol M., Cesareni G., and Blandino G. Physical interaction with Yes-associated protein (YAP) enhances p73 transcriptional activity. J. Biol. Chem. 2001;276:15164-173.
46. Strano S., Rossi M., Fontemaggi, G., Munarriz, E., Soddu, S., Sacchi, A., and Blandino G. From p63 to p53 across p73. FEBS Lett. 2001;490:163-70.
47. Strano S., and Blandino G. p73-mediated chemosensitivity: a preferential target of oncogenic mutant p53. Cell Cycle. 2003;2:348-9.
48. Sudol M. Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. Oncogene 1994;9:2145-52.
49. Trink B., Okami K., Wu L., Sriuranpong V., Jen J., and Sidransky. D. A new human p53 homologue. Nat. Med. 1998;4:747-8.
50. Yang, A., N. Walker, R. Bronson, M. Kaghad, M. Oosterwegel, J. Bonnin, C. Vagner, H. Bonnet, P. Dikkes, A. Sharpe, F. McKeon, and D. Caput. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 2000;404:99-103.
51. Yang A., and McKeon. F. p63 and p73:p53 mimics, menaces and more. Nat. Rev. Mol. Cell. Biol. 2000;1:199-207.
52. Yang A., Schweitzer R., Sun D., Kaghad M., Walker N., Bronson R. T., Tabin C., Sharpe A., Caput D., Crum C., and McKeon F. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999;398:714-8.
53. Yang A., Kaghad M., Wang, Y., Gillett E., Fleming M. D., Dotsch V., Andrews N. C., Caput D., and McKeon. F. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell. 1998;2:305-16.
54. Yonish-Rouach E., Resnitzky D., Lotem J., Sachs L., Kimchi A., and Oren M. Wild type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991, 352:345-47.
55. Yuan Z. M., Shioya H,. Ishiko T, Sun X., Gu J., Huang Y. Y., Lu H., Kharbanda S., Weichselbaum R., and Kufe. D. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 1999;399:814-17.